David Ramsey to Hypoglycemic Agents
This is a "connection" page, showing publications David Ramsey has written about Hypoglycemic Agents.
Connection Strength
0.254
-
Rehman H, Akeroyd JM, Ramsey D, Ahmed ST, Merchant AT, Navaneethan SD, Petersen LA, Virani SS. Facility-level variation in diabetes and blood pressure control in patients with diabetes: Findings from the Veterans Affairs national database. Clin Cardiol. 2017 Nov; 40(11):1055-1060.
Score: 0.125
-
Al Rifai M, Vaughan EM, Abushamat LA, Lee M, Ramsey DJ, Gupta K, Navaneethan SD, Virani SS. Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs). Am J Cardiol. 2022 06 01; 172:7-10.
Score: 0.043
-
Mahtta D, Ramsey DJ, Lee MT, Chen L, Al Rifai M, Akeroyd JM, Vaughan EM, Matheny ME, Santo KRDE, Navaneethan SD, Lavie CJ, Birnbaum Y, Ballantyne CM, Petersen LA, Virani SS. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
Score: 0.043
-
Al Rifai M, Mahtta D, Ramsey DJ, Lee MT, Krittanawong C, Navaneethan SD, Gregg LP, Petersen LA, Virani SS. Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. Am Heart J. 2022 06; 248:160-162.
Score: 0.042